Leadmego

“Because Genentech is a leading developer of cancer therapies, some doctors also fear that the company’s pricing plans for Avastin – around $8,800 a month – may encourage other companies to charge more for their own oncology drugs.”

Quotes by Alex Berenson

Leave a Reply

Your email address will not be published. Required fields are marked *